Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06967805 · ClinicalTrials.gov registry record · Phase 2
WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)
A Phase 2 study of Idiopathic Pulmonary Fibrosis, sponsored by Mediar Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 164
- Enrollment target
- 20
- Study locations
NCT06967805: Recruiting Phase 2 study of Idiopathic Pulmonary Fibrosis, sponsored by Mediar Therapeutics.
NCT06967805 is a Phase 2 study of Idiopathic Pulmonary Fibrosis that is actively recruiting participants, run by Mediar Therapeutics. The registered enrollment target is 164 participants, below the 748-participant average among 51 other Idiopathic Pulmonary Fibrosis trials with a reported enrollment target (78% lower). The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06967805, a Phase 2 study of Idiopathic Pulmonary Fibrosis, is actively recruiting participants, sponsored by Mediar Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 164 participants
- Enrollment target
- 20
- Study locations
Study Summary
A Phase 2a, Randomized, Double-blind, Placebo-Controlled Study of the Safety and Efficacy of MTX-463 in Participants with Idiopathic Pulmonary Fibrosis (IPF)
Primary Outcome
Change from Baseline to Week 24 in Forced Vital Capacity (FVC)
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL MTX-463
Study Locations (20)
California
- WISPer Site in Los Angeles, CA - Los Angeles
- WISPer site in Newport Beach, CA - Newport Beach
- WISPer Site in Palm Springs, CA - Palm Springs
Michigan
- WISPer Site in Ann Arbor, MI - Ann Arbor
- WISPer Site in Detroit, MI - Detroit
North Carolina
- WISPer Site in Durham, NC - Durham
- WISPer site in Greensboro, NC - Greensboro
Alabama
- WISPer Site in Birmingham, AL - Birmingham
Arizona
- WISPer site in Phoenix, AZ - Phoenix
Colorado
- WISPer Site in Denver, CO - Denver
Florida
- WISPer site in Loxahatchee, FL - Loxahatchee Groves
Illinois
- WISPer site in Champaign, IL - Champaign
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 164 participants |
| Start Date | 2025-05-05 |
| Est. Completion | 2027-08 |
| Phase | Phase 2 |
What NCT06967805 shows while recruiting
NCT06967805 is an interventional study that assigns participants to a tested intervention. The registered 164 participants enrollment target is mid-sized for trials with a published cap, below the 748-participant average among 51 other Idiopathic Pulmonary Fibrosis trials with a reported enrollment target (78% lower).
The record links to 1 condition, with Idiopathic Pulmonary Fibrosis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06967805 names 20 study sites across 16 states, led by California, Michigan, North Carolina.
Frequently Asked Questions
What is clinical trial NCT06967805 about?
NCT06967805 is a clinical study titled "WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)". A Phase 2a, Randomized, Double-blind, Placebo-Controlled Study of the Safety and Efficacy of MTX-463 in Participants with Idiopathic Pulmonary Fibrosis (IPF)
What is the current status of trial NCT06967805?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 164 participants. The study started on 2025-05-05. Estimated completion is 2027-08.
What conditions does trial NCT06967805 study?
This clinical trial studies the following conditions: Idiopathic Pulmonary Fibrosis.
What interventions are being tested in trial NCT06967805?
The interventions under investigation include: Placebo (OTHER), MTX-463 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06967805?
This trial is sponsored by Mediar Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06967805 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Idiopathic Pulmonary Fibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06967805's enrollment target sits among peer trials
164 17th of 51 higher than 35 of 51 other Idiopathic Pulmonary Fibrosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Idiopathic Pulmonary Fibrosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis
RECRUITING · Phase 2
-
Zinc and Nicotinamide Riboside for Idiopathic Pulmonary Fibrosis
RECRUITING · Phase 2
-
A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard Treatment
RECRUITING · Phase 2
-
A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the Blood
RECRUITING · Phase 2
-
H01 in Adults With Interstitial Lung Disease (The SOLIS Study)
RECRUITING · Phase 2
-
Study of ABBV-142 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Idiopathic Pulmonary Fibrosis
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04891289 · 164 participants · Phase 2
Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With Surgery
- NCT04893226 · 164 participants · NA
Time-Restricted Feeding Intervention in Metabolically-Unhealthy Postmenopausal Women
- NCT05270213 · 164 participants · Phase 1
Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors
- NCT05543681 · 164 participants · Phase 2
Clinical Trial on Agitation in Alzheimer's Dementia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI